PE20161099A1 - Nuevos inhibidores de dgta2 - Google Patents
Nuevos inhibidores de dgta2Info
- Publication number
- PE20161099A1 PE20161099A1 PE2016000674A PE2016000674A PE20161099A1 PE 20161099 A1 PE20161099 A1 PE 20161099A1 PE 2016000674 A PE2016000674 A PE 2016000674A PE 2016000674 A PE2016000674 A PE 2016000674A PE 20161099 A1 PE20161099 A1 PE 20161099A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- dgta2
- new inhibitors
- treatment
- dgat2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908339P | 2013-11-25 | 2013-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161099A1 true PE20161099A1 (es) | 2016-10-22 |
Family
ID=52016867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000674A PE20161099A1 (es) | 2013-11-25 | 2014-11-19 | Nuevos inhibidores de dgta2 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9073901B2 (fr) |
| EP (1) | EP3074381B1 (fr) |
| JP (1) | JP6155395B2 (fr) |
| KR (1) | KR20160072252A (fr) |
| CN (1) | CN105764889B (fr) |
| AP (1) | AP2016009230A0 (fr) |
| AR (1) | AR098394A1 (fr) |
| AU (1) | AU2014353109B2 (fr) |
| CA (1) | CA2928468A1 (fr) |
| CL (1) | CL2016001172A1 (fr) |
| CR (1) | CR20160216A (fr) |
| DO (1) | DOP2016000120A (fr) |
| EA (1) | EA201690847A1 (fr) |
| ES (1) | ES2695302T3 (fr) |
| HK (1) | HK1223367A1 (fr) |
| IL (1) | IL245245A0 (fr) |
| MA (1) | MA39048B1 (fr) |
| MX (1) | MX2016006665A (fr) |
| NZ (1) | NZ719444A (fr) |
| PE (1) | PE20161099A1 (fr) |
| PH (1) | PH12016500963A1 (fr) |
| TN (1) | TN2016000146A1 (fr) |
| TW (1) | TW201609668A (fr) |
| WO (1) | WO2015077299A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10053429B2 (en) | 2015-05-20 | 2018-08-21 | Eli Lilly And Company | DGAT2 inhibitors |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| EP4153596A1 (fr) | 2020-05-18 | 2023-03-29 | Merck Sharp & Dohme LLC | Nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 |
| AR123700A1 (es) | 2020-10-08 | 2023-01-04 | Merck Sharp & Dohme | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 |
| EP4247787A2 (fr) | 2020-11-20 | 2023-09-27 | 2692372 Ontario, Inc. | Procédés et composition pour effectuer des modifications de kras |
| WO2023026180A1 (fr) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Forme amorphe de (s)-2-(5-((3-éthoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tétrahydrofuran-3-yl)pyrimidine-5-carboxamide |
| WO2024118858A1 (fr) | 2022-12-02 | 2024-06-06 | Merck Sharp & Dohme Llc | Préparation de dérivés d'azole fusionnés utilisés en tant que nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003053363A2 (fr) | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Membres de la famille des diacylglycerol-acyltransferases 2 (dgat2) et leurs utilisations |
| CA2492225A1 (fr) | 2002-07-18 | 2004-01-29 | Merck & Co., Inc. | Polytherapie pour le traitement de l'obesite |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| PE20060530A1 (es) * | 2004-06-04 | 2006-06-28 | Arena Pharm Inc | Aril y heteroaril derivados sustituidos como moduladores del metabolismo de la glucosa |
| WO2006049933A2 (fr) | 2004-10-29 | 2006-05-11 | Merck & Co., Inc. | Compositions et procedes de traitement de l'obesite et du dysfonctionnement sexuel |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| US8987198B2 (en) | 2009-12-22 | 2015-03-24 | The Administrators Of The Tulane Educational Fund | Compositions and methods for treating obesity and diabetes |
| WO2011078102A1 (fr) * | 2009-12-22 | 2011-06-30 | 第一三共株式会社 | Nouveau dérivé de phénoxypyrimidine |
| CN102933561B (zh) * | 2010-03-22 | 2016-05-11 | 利德发现中心有限责任公司 | 具有药学活性的二取代三嗪衍生物 |
| EP2680849A4 (fr) * | 2011-03-03 | 2015-02-18 | Univ Vanderbilt | Analogues de 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide en tant que modulateurs allostériques négatifs de mglur5 et procédé pour les préparer et les utiliser |
| EP2561867A1 (fr) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Inhibiteurs de CDK9 pour le traitement du carcinome de la ligne médiane |
| EP2562265A1 (fr) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Sensibilité à des inhibiteurs sélectifs de CDK9 |
| PE20142164A1 (es) | 2012-04-06 | 2014-12-27 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
-
2014
- 2014-11-12 AR ARP140104254A patent/AR098394A1/es unknown
- 2014-11-13 TW TW103139445A patent/TW201609668A/zh unknown
- 2014-11-19 NZ NZ719444A patent/NZ719444A/en not_active IP Right Cessation
- 2014-11-19 CA CA2928468A patent/CA2928468A1/fr not_active Abandoned
- 2014-11-19 KR KR1020167013324A patent/KR20160072252A/ko not_active Application Discontinuation
- 2014-11-19 CN CN201480064300.4A patent/CN105764889B/zh active Active
- 2014-11-19 MA MA39048A patent/MA39048B1/fr unknown
- 2014-11-19 AU AU2014353109A patent/AU2014353109B2/en not_active Ceased
- 2014-11-19 AP AP2016009230A patent/AP2016009230A0/en unknown
- 2014-11-19 US US14/547,615 patent/US9073901B2/en active Active
- 2014-11-19 JP JP2016532611A patent/JP6155395B2/ja not_active Expired - Fee Related
- 2014-11-19 MX MX2016006665A patent/MX2016006665A/es unknown
- 2014-11-19 EP EP14809734.8A patent/EP3074381B1/fr active Active
- 2014-11-19 TN TN2016000146A patent/TN2016000146A1/en unknown
- 2014-11-19 WO PCT/US2014/066339 patent/WO2015077299A1/fr active Application Filing
- 2014-11-19 PE PE2016000674A patent/PE20161099A1/es not_active Application Discontinuation
- 2014-11-19 ES ES14809734T patent/ES2695302T3/es active Active
- 2014-11-19 EA EA201690847A patent/EA201690847A1/ru unknown
-
2016
- 2016-04-20 IL IL245245A patent/IL245245A0/en unknown
- 2016-05-05 CR CR20160216A patent/CR20160216A/es unknown
- 2016-05-16 CL CL2016001172A patent/CL2016001172A1/es unknown
- 2016-05-24 DO DO2016000120A patent/DOP2016000120A/es unknown
- 2016-05-24 PH PH12016500963A patent/PH12016500963A1/en unknown
- 2016-10-06 HK HK16111635.0A patent/HK1223367A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2695302T3 (es) | 2019-01-03 |
| TW201609668A (zh) | 2016-03-16 |
| AP2016009230A0 (en) | 2016-05-31 |
| IL245245A0 (en) | 2016-06-30 |
| JP2016539115A (ja) | 2016-12-15 |
| PH12016500963A1 (en) | 2016-06-20 |
| AU2014353109A1 (en) | 2016-05-12 |
| JP6155395B2 (ja) | 2017-06-28 |
| NZ719444A (en) | 2017-12-22 |
| EP3074381A1 (fr) | 2016-10-05 |
| DOP2016000120A (es) | 2016-06-15 |
| HK1223367A1 (zh) | 2017-07-28 |
| EA201690847A1 (ru) | 2016-09-30 |
| CL2016001172A1 (es) | 2016-12-09 |
| WO2015077299A1 (fr) | 2015-05-28 |
| AU2014353109B2 (en) | 2017-02-02 |
| MX2016006665A (es) | 2016-07-26 |
| CR20160216A (es) | 2016-06-27 |
| US9073901B2 (en) | 2015-07-07 |
| US20150148358A1 (en) | 2015-05-28 |
| CN105764889B (zh) | 2018-01-02 |
| AR098394A1 (es) | 2016-05-26 |
| EP3074381B1 (fr) | 2018-07-04 |
| MA39048B1 (fr) | 2018-04-30 |
| MA39048A1 (fr) | 2017-05-31 |
| CA2928468A1 (fr) | 2015-05-28 |
| TN2016000146A1 (en) | 2017-10-06 |
| CN105764889A (zh) | 2016-07-13 |
| KR20160072252A (ko) | 2016-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161099A1 (es) | Nuevos inhibidores de dgta2 | |
| PH12018502534B1 (en) | Heteroaryl substituted pyridines and methods of use | |
| PH12017502201A1 (en) | Substituted pyridines and method of use | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2017005668A (es) | Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. | |
| TN2017000134A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| WO2012061428A3 (fr) | Nicotinamides en tant que modulateurs des jak kinases | |
| WO2012143796A3 (fr) | Composés anti-inflammatoires | |
| NZ631337A (en) | Prodrugs of fumarates and their use in treating various diseases | |
| MY176814A (en) | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| NZ707083A (en) | Anti-fibrotic pyridinones | |
| EA201391668A1 (ru) | Способы лечения или предупреждения связанных с холестерином расстройств | |
| MY183582A (en) | Deuterated cftr potentiators | |
| EA201391615A1 (ru) | Дейтерированные потенциаторы cftr | |
| EA201391230A1 (ru) | Соединения и композиции в качестве ингибиторов trk | |
| IN2014CN03803A (fr) | ||
| WO2012173682A3 (fr) | Composés et méthodes de traitement de maladies liées à l'isocitrate déshydrogénase | |
| MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
| MY150437A (en) | Hydroxamate-based inhibitors of deacetylases b | |
| EP3147360A4 (fr) | Transformant de bactérie coryneforme présentant un niveau élevé d'expression d'enzyme variante hautement active et procédé de production d'acide 4-hydroxybenzoïque l'utilisant ou de son sel | |
| ZA201508750B (en) | Compounds of '3-(5-sustituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester', process and applications thereof | |
| MY173914A (en) | Pesticidal composition and method for controlling pests | |
| WO2013172741A3 (fr) | Acides (3r,4r,5s)-5-guanidino-4-acylamino-3-(pentan-3-yloxy) cyclohexène-1-carboniques substitués en fluor, leurs éthers, et procédé d'utilisation | |
| MY184030A (en) | Biological production of methyl methacrylate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |